862508-03-0Relevant articles and documents
Preparation method of capecitabine impurity (5-fluoro-2-oxo-1,2-dihydropyrimidine-4-yl)amylcarbamate
-
Paragraph 0007; 0024-0030, (2019/02/26)
The invention discloses a preparation method of a capecitabine impurity (5-fluoro-2-oxo-1,2-dihydropyrimidine-4-yl)amylcarbamate. According to the method, 5-flucytosine and n-amyl chloroformate reactin an organic solvent to produce (5-fluoro-2-oxo-1,2-dihydropyrimidine-4-yl)amylcarbamate with pyridine as an acid binding agent and tetrabutylammonium bromide as a phase transfer catalyst. The preparation method comprises simple steps, the yield (90% or higher) is high, and the prepared product has higher purity (99% or higher) and can be completely used as an impurity reference substance to be used for quality research of capecitabine.
Capecitabine preparation method
-
Paragraph 0041; 0046; 0047, (2016/10/10)
The invention discloses a capecitabine preparation method; 5-FU as a raw material is subjected to a reaction with pentyloxy formyl chloride, then an intermediate is generated and then is coupled with a ribose derivative, an ethoxyl protective group of ethoxyl of the ribose derivative is removed in the coupling reaction, and thus the target compound capecitabine is obtained; the method comprises the following steps: step one, the 5-FU as the raw material is subjected to the reaction with pentyloxy formyl chloride, and then the intermediate is generated; and step two, the intermediate is coupled with the ribose derivative to generate the product capecitabine. The production cost can be saved, the medical expense of patients is reduced, the side effect is reduced, and the yield is higher.
METHOD FOR THE PREPARATION OF CAPECITABINE AND INTERMEDIATES USED IN SAID METHOD
-
Page/Page column 9, (2010/11/03)
A process to obtain capecitabine compound and its pharmaceutically acceptable derivatives is hereby disclosed. Likewise, novel intermediates to be used in the preparation of capecitabine compound and its pharmaceutically acceptable derivatives are also disclosed. The procedure comprises the stage of causing a reaction of N4-(n-pentyloxycarbonyl))-5- fluorocytosine with (1,2,3-tri-O-acetyl-5-deoxy- α,β-D-ribofuranose.